Mohs surgery for melanoma: rationale, advances and possibilities

References

• Mohs FE. Chemosurgery: a microscopically controlled method of excision. Arch. Surg.42, 279–295 (1941).
   Google Scholar
• Mohs FE. Chemosurgical treatment of melanoma: a microscopically controlled method of excision. Arch. Dermatol. Syphilol.62, 269–279 (1950).
   PubMedGoogle Scholar
• Mohs FE. Microscopically controlled surgery for periorbital melanoma: fixed-tissue and fresh-tissue techniques. J. Dermatol. Surg. Oncol.11(3), 284–291 (1985).
   PubMedGoogle Scholar
• Zitelli JA, Mohs FE, Larson P, Snow S. Mohs micrographic surgery for melanoma. Dermatol. Clin.7(4), 833–843 (1989).
   PubMedGoogle Scholar
• Veronesi U, Cascinelli N, Adamus J et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N. Engl. J. Med.318(18), 1159–1162 (1988).
   PubMed Web of Science ®Google Scholar
• NIH Consensus conference. Diagnosis and treatment of early melanoma. JAMA268(10), 1314–1319 (1992).
   PubMed Web of Science ®Google Scholar
• Robinson JK. Margin control for lentigo maligna. J. Am. Acad. Dermatol.31(1), 79–85 (1994).
   PubMed Web of Science ®Google Scholar
• Zalla MJ, Lim KK, Dicaudo DJ, Gagnot MM. Mohs micrographic excision of melanoma using immunostains. Dermatol. Surg.26(8), 771–784 (2000).
   PubMedGoogle Scholar
• Agarwal-Antal N, Bowen GM, Gerwels JW. Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J. Am. Acad. Dermatol.47(5), 743–748 (2002).
   PubMed Web of Science ®Google Scholar
• Albertini JG, Elston DM, Libow LF, Smith SB, Farley MF. Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping technique. Dermatol. Surg.28(8), 656–665 (2002).
   PubMedGoogle Scholar
• Huilgol SC, Selva D, Chen C et al. Surgical margins for lentigo maligna and lentigo maligna melanoma: the technique of mapped serial excision. Arch. Dermatol.140(9), 1087–1092 (2004).
   PubMedGoogle Scholar
• Malhotra R, Chen C, Huilgol SC, Hill DC, Selva D. Mapped serial excision for periocular lentigo maligna and lentigo maligna melanoma. Ophthalmology110(10), 2011–2018 (2003).
   PubMed Web of Science ®Google Scholar
• Cohn-Cedermark G, Rutqvist LE, Andersson R et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8–2.0 mm. Cancer89(7), 1495–1501 (2000).
   PubMed Web of Science ®Google Scholar
• Balch CM, Soong SJ, Smith T et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1–4 mm melanomas. Ann. Surg. Oncol.8(2), 101–108 (2001).
   PubMed Web of Science ®Google Scholar
• Thomas JM, Newton-Bishop J, A’Hern R et al. Excision margins in high-risk malignant melanoma. N. Engl. J. Med.350(8), 757–766 (2004).
   PubMed Web of Science ®Google Scholar
• Heaton KM, Sussman JJ, Gershenwald JE et al. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann. Surg. Oncol.5(4), 322–328 (1998).
   PubMed Web of Science ®Google Scholar
• Zitelli JA, Brown CD, Hanusa BH. Surgical margins for excision of primary cutaneous melanoma. J. Am. Acad. Dermatol.37(3 Pt 1), 422–429 (1997).
   PubMed Web of Science ®Google Scholar
• Bricca GM, Brodland DG, Ren D, Zitelli JA. Cutaneous head and neck melanoma treated with Mohs micrographic surgery. J. Am. Acad. Dermatol.52(1), 92–100 (2005).
   PubMedGoogle Scholar
• Cohen LM, McCall MW, Hodge SJ, Freedman JD, Callen JP, Zax RH. Successful treatment of lentigo maligna and lentigo maligna melanoma with Mohs’ micrographic surgery aided by rush permanent sections. Cancer73(12), 2964–2970 (1994).
   PubMed Web of Science ®Google Scholar
• Barlow RJ, White CR, Swanson NA. Mohs’ micrographic surgery using frozen sections alone may be unsuitable for detecting single atypical melanocytes at the margins of melanoma in situ. Br. J. Dermatol.146(2), 290–294 (2002).
   PubMedGoogle Scholar
• Prieto VG, Argenyi ZB, Barnhill RL et al. Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions? Am. J. Clin. Pathol.120(2), 203–208 (2003).
   PubMed Web of Science ®Google Scholar
• Zitelli JA, Moy RL, Abell E. The reliability of frozen sections in the evaluation of surgical margins for melanoma. J. Am. Acad. Dermatol.24(1), 102–106 (1991).
   PubMed Web of Science ®Google Scholar
• Bene NI, Healy C, Coldiron BM. Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases. Dermatol. Surg.34(5), 660–664 (2008).
   PubMed Web of Science ®Google Scholar
• Busam KJ, Chen YT, Old LJ et al. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am. J. Surg. Pathol.22(8), 976–982 (1998).
   PubMed Web of Science ®Google Scholar
• Jungbluth AA, Busam KJ, Gerald WL et al. A103: an anti-melan-A monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am. J. Surg. Pathol.22(5), 595–602 (1998).
   PubMedGoogle Scholar
• Cormier JN, Hijazi YM, Abati A et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int. J. Cancer75(4), 517–524 (1998).
   PubMed Web of Science ®Google Scholar
• Blessing K, Sanders DS, Grant JJ. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology32(2), 139–146 (1998).
   PubMed Web of Science ®Google Scholar
• de Vries TJ, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ, van Muijen GN. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res.57(15), 3223–3229 (1997).
   PubMed Web of Science ®Google Scholar
• Chang KH, Finn DT, Lee D, Bhawan J, Dallal GE, Rogers GS. Novel 16-minute technique for evaluating melanoma resection margins during Mohs surgery. J. Am. Acad. Dermatol.64(1), 107–112 (2011).
   PubMedGoogle Scholar
• El Shabrawi-Caelen L, Kerl H, Cerroni L. Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis. Am. J. Dermatopathol.26(5), 364–366 (2004).
   PubMed Web of Science ®Google Scholar
• Maize JC Jr, Resneck JS Jr, Shapiro PE, McCalmont TH, LeBoit PE. Ducking stray ‘magic bullets’: a melan-A alert. Am. J. Dermatopathol.25(2), 162–165 (2003).
   PubMedGoogle Scholar
• Beltraminelli H, Shabrawi-Caelen LE, Kerl H, Cerroni L. Melan-A-positive ‘pseudomelanocytic nests’: a pitfall in the histopathologic and immunohistochemical diagnosis of pigmented lesions on sun-damaged skin. Am. J. Dermatopathol.31(3), 305–308 (2009).
   PubMed Web of Science ®Google Scholar
• Bricca GM, Brodland DG, Zitelli JA. Immunostaining melanoma frozen sections: the 1-hour protocol. Dermatol. Surg.30(3), 403–408 (2004).
   PubMed Web of Science ®Google Scholar
• Kimyai-Asadi A, Ayala GB, Goldberg LH, Vujevich J, Jih MH. The 20-minute rapid MART-1 immunostain for malignant melanoma frozen sections. Dermatol. Surg.34(4), 498–500 (2008).
   PubMed Web of Science ®Google Scholar
• Cherpelis BS, Moore R, Ladd S, Chen R, Glass LF. Comparison of MART-1 frozen sections to permanent sections using a rapid 19-minute protocol. Dermatol. Surg.35(2), 207–213 (2009).
   PubMed Web of Science ®Google Scholar
• Hemesath TJ, Steingrimsson E, McGill G et al. microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev.8(22), 2770–2780 (1994).
   PubMed Web of Science ®Google Scholar
• Yasumoto K, Yokoyama K, Shibata K, Tomita Y, Shibahara S. Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene. Mol. Cell. Biol.14(12), 8058–8070 (1994).
   PubMed Web of Science ®Google Scholar
• Bentley NJ, Eisen T, Goding CR. Melanocyte-specific expression of the human tyrosinase promoter: activation by the microphthalmia gene product and role of the initiator. Mol. Cell. Biol.14(12), 7996–8006 (1994).
   PubMed Web of Science ®Google Scholar
• McGill GG, Horstmann M, Widlund HR et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell109(6), 707–718 (2002).
   PubMed Web of Science ®Google Scholar
• King R, Weilbaecher KN, McGill G, Cooley E, Mihm M, Fisher DE. Microphthalmia transcription factor. A sensitive and specific melanocyte marker for MelanomaDiagnosis. Am. J. Pathol.155(3), 731–738 (1999).
   PubMed Web of Science ®Google Scholar
• King R, Googe PB, Weilbaecher KN, Mihm MC Jr, Fisher DE. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am. J. Surg. Pathol.25(1), 51–57 (2001).
   PubMed Web of Science ®Google Scholar
• Miettinen M, Fernandez M, Franssila K, Gatalica Z, Lasota J, Sarlomo-Rikala M. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am. J. Surg. Pathol.25(2), 205–211 (2001).
   PubMed Web of Science ®Google Scholar
• Granter SR, Weilbaecher KN, Quigley C, Fletcher CD, Fisher DE. Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma. Am. J. Dermatopathol.23(3), 185–189 (2001).
   PubMed Web of Science ®Google Scholar
• Busam KJ, Iversen K, Coplan KC, Jungbluth AA. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am. J. Surg. Pathol.25(2), 197–204 (2001).
   PubMed Web of Science ®Google Scholar
• Glass LF, Raziano RM, Clark GS et al. Rapid frozen section immunostaining of melanocytes by microphthalmia-associated transcription factor. Am. J. Dermatopathol.32(4), 319–325 (2010).
   PubMed Web of Science ®Google Scholar
• Blake BCG, Cherpelis BS, Ladd S, Glass LF. Melanocyte density and nuclear size distinguishes melanoma in situ (MIS) from solar lentigo/lentiginous melanocytic hyperplasia (LMH). Am. J. Dermatopathol.31, 411 (2009).
   Google Scholar
• Chiamenti AM, Vella F, Bonetti F et al. Anti-melanoma monoclonal antibody HMB-45 on enhanced chemiluminescence-western blotting recognizes a 30–35 kDa melanosome-associated sialated glycoprotein. Melanoma Res.6(4), 291–298 (1996).
   PubMedGoogle Scholar
• Kikuchi A, Shimizu H, Nishikawa T. Expression and ultrastructural localization of HMB-45 antigen. Br. J. Dermatol.135(3), 400–405 (1996).
   PubMedGoogle Scholar
• Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am. J. Pathol.123(2), 195–203 (1986).
   PubMed Web of Science ®Google Scholar
• Wick MR, Swanson PE, Rocamora A. Recognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumors. J. Cutan. Pathol.15(4), 201–207 (1988).
   PubMedGoogle Scholar
• Ordonez NG, Ji XL, Hickey RC. Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohistochemical diagnosis of melanoma. Am. J. Clin. Pathol.90(4), 385–390 (1988).
   PubMedGoogle Scholar
• Fernando SS, Johnson S, Bate J. Immunohistochemical analysis of cutaneous malignant melanoma: comparison of S-100 protein, HMB-45 monoclonal antibody and NKI/C3 monoclonal antibody. Pathology26(1), 16–19 (1994).
   PubMed Web of Science ®Google Scholar
• Duray PH, Palazzo J, Gown AM, Ohuchi N. Melanoma cell heterogeneity. A study of two monoclonal antibodies compared with S-100 protein in paraffin sections. Cancer61(12), 2460–2468 (1988).
   PubMedGoogle Scholar
• Skelton HG 3rd, Smith KJ, Barrett TL, Lupton GP, Graham JH. HMB-45 staining in benign and malignant melanocytic lesions. A reflection of cellular activation. Am. J. Dermatopathol.13(6), 543–550 (1991).
   PubMedGoogle Scholar
• Lampert A, Thomine E, Lauret P, Hemet J. [Comparative study of HMB-45 monoclonal antibody uptake on various benign and malignant melanocytic lesions]. Ann. Pathol.13(2), 100–107 (1993).
   PubMedGoogle Scholar
• Menaker GM, Chiang JK, Tabila B, Moy RL. Rapid HMB-45 staining in Mohs micrographic surgery for melanoma in situ and invasive melanoma. J. Am. Acad. Dermatol.44(5), 833–836 (2001).
   PubMedGoogle Scholar
• Anstey A, Cerio R, Ramnarain N, Orchard G, Smith N, Jones EW. Desmoplastic malignant melanoma. An immunocytochemical study of 25 cases. Am. J. Dermatopathol.16(1), 14–22 (1994).
   PubMed Web of Science ®Google Scholar
• Gross EA, Andersen WK, Rogers GS. Mohs micrographic excision of lentigo maligna using Mel-5 for margin control. Arch. Dermatol.135(1), 15–17 (1999).
   PubMedGoogle Scholar
• Bhardwaj SS, Tope WD, Lee PK. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma using Mel-5 immunostaining: University of Minnesota experience. Dermatol. Surg.32(5), 690–696; discussion 696–697 (2006).
   PubMed Web of Science ®Google Scholar
• Bhawan J. Mel-5: a novel antibody for differential diagnosis of epidermal pigmented lesions of the skin in paraffin-embedded sections. Melanoma Res.7(1), 43–48 (1997).
   PubMedGoogle Scholar
• Abide JM, Nahai F, Bennett RG. The meaning of surgical margins. Plast. Reconstr. Surg.73(3), 492–497 (1984).
   PubMed Web of Science ®Google Scholar
• McKinnon JG, Starritt EC, Scolyer RA, McCarthy WH, Thompson JF. Histopathologic excision margin affects local recurrence rate: analysis of 2681 patients with melanomas < or =2 mm thick. Ann. Surg.241(2), 326–333 (2005).
   PubMedGoogle Scholar
• DeBloom JR 2nd, Zitelli JA, Brodland DG. The invasive growth potential of residual melanoma and melanoma in situ. Dermatol. Surg.36(8), 1251–1257 (2010).
   PubMedGoogle Scholar
• Wildemore JK, Schuchter L, Mick R et al. Locally recurrent malignant melanoma characteristics and outcomes: a single-institution study. Ann. Plast. Surg.46(5), 488–494 (2001).
   PubMedGoogle Scholar
• Madden K, Forman SB, Elston D. Quantification of melanocytes in sun-damaged skin. J. Am. Acad. Dermatol.64(3), 548–552 (2011).
   PubMedGoogle Scholar
• Osborne JE, Hutchinson PE. A follow-up study to investigate the efficacy of initial treatment of lentigo maligna with surgical excision. Br. J. Plast. Surg.55(8), 611–615 (2002).
   PubMedGoogle Scholar
• Pitman GH, Kopf AW, Bart RS, Casson PR. Treatment of lentigo maligna and lentigo maligna melanoma. J. Dermatol. Surg. Oncol.5(9), 727–737 (1979).
   PubMedGoogle Scholar
• Coleman WP 3rd, Davis RS, Reed RJ, Krementz ET. Treatment of lentigo maligna and lentigo maligna melanoma. J. Dermatol. Surg. Oncol.6(6), 476–479 (1980).
   PubMedGoogle Scholar
• Cohen LM, McCall MW, Zax RH. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. A follow-up study. Dermatol. Surg.24(6), 673–677 (1998).
   PubMed Web of Science ®Google Scholar
• Temple CL, Arlette JP. Mohs micrographic surgery in the treatment of lentigo maligna and melanoma. J. Surg. Oncol.94(4), 287–292 (2006).
   PubMed Web of Science ®Google Scholar
• Walling HW, Scupham RK, Bean AK, Ceilley RI. Staged excision versus Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. J. Am. Acad. Dermatol.57(4), 659–664 (2007).
   PubMed Web of Science ®Google Scholar
• Zitelli JA, Brown C, Hanusa BH. Mohs micrographic surgery for the treatment of primary cutaneous melanoma. J. Am. Acad. Dermatol.37(2 Pt 1), 236–245 (1997).
   PubMedGoogle Scholar
• Megahed M, Schon M, Selimovic D, Schon MP. Reliability of diagnosis of melanoma in situ.Lancet359(9321), 1921–1922 (2002).
   PubMed Web of Science ®Google Scholar
• Bub JL, Berg D, Slee A, Odland PB. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up. Arch. Dermatol.140(5), 552–558 (2004).
   PubMedGoogle Scholar
• Bosbous MW, Dzwierzynski WW, Neuburg M. Staged excision of lentigo maligna and lentigo maligna melanoma: a 10-year experience. Plast. Reconstr. Surg.124(6), 1947–1955 (2009).
   PubMedGoogle Scholar
• Mahoney MH, Joseph M, Temple CL. The perimeter technique for lentigo maligna: an alternative to Mohs micrographic surgery. J. Surg. Oncol.91(2), 120–125 (2005).
   PubMed Web of Science ®Google Scholar
• Gaudy-Marqueste C, Perchenet AS, Tasei AM et al. The ‘spaghetti technique’: an alternative to Mohs surgery or staged surgery for problematic lentiginous melanoma (lentigo maligna and acral lentiginous melanoma). J. Am. Acad. Dermatol.64(1), 113–118 (2011).
   PubMedGoogle Scholar
• Hill DC, Gramp AA. Surgical treatment of lentigo maligna and lentigo maligna melanoma. Australas J. Dermatol.40(1), 25–30 (1999).
   PubMedGoogle Scholar
• Hazan C, Dusza SW, Delgado R, Busam KJ, Halpern AC, Nehal KS. Staged excision for lentigo maligna and lentigo maligna melanoma: A retrospective analysis of 117 cases. J. Am. Acad. Dermatol.58(1), 142–148 (2008).
   PubMed Web of Science ®Google Scholar
• Snow SN, Mohs FE, Oriba HA, Dudley CM, Leverson G, Hetzer M. Cutaneous malignant melanoma treated by Mohs surgery. Review of the treatment results of 179 cases from the Mohs Melanoma Registry. Dermatol. Surg.23(11), 1055–1060 (1997).
   PubMedGoogle Scholar
• Esmaeli B, Youssef A, Naderi A, Ahmadi MA, Meyer DR, McNab A. Margins of excision for cutaneous melanoma of the eyelid skin: the Collaborative Eyelid Skin Melanoma Group Report. Ophthal. Plast. Reconstr. Surg.19(2), 96–101 (2003).
   PubMedGoogle Scholar
• Then SY, Malhotra R, Barlow R et al. Early cure rates with narrow-margin slow-Mohs surgery for periocular malignant melanoma. Dermatol. Surg.35(1), 17–23 (2009).
   PubMed Web of Science ®Google Scholar
• Brodland DG. The treatment of nail apparatus melanoma with Mohs micrographic surgery. Dermatol. Surg.27(3), 269–273 (2001).
   PubMedGoogle Scholar
• Banfield CC, Dawber RP, Walker NP, Stables GI, Zeina B, Schomberg K. Mohs micrographic surgery for the treatment of in situ nail apparatus melanoma: a case report. J. Am. Acad. Dermatol.40(1), 98–99 (1999).
   PubMedGoogle Scholar
• High WA, Quirey RA, Guillen DR, Munoz G, Taylor RS. Presentation, histopathologic findings, and clinical outcomes in 7 cases of melanoma in situ of the nail unit. Arch. Dermatol.140(9), 1102–1106 (2004).
   PubMedGoogle Scholar
• Kim S, Brock GB, Temple CL. Minimizing morbidity in the treatment of penile melanoma: Mohs micrographic surgery and sentinel lymph node biopsy. Can. J. Urol.14(1), 3467–3470 (2007).
   PubMedGoogle Scholar
• Dhawan SS, Wolf DJ, Rabinovitz HS, Poulos E. Lentigo maligna. The use of rush permanent sections in therapy. Arch. Dermatol.126(7), 928–930 (1990).
   PubMedGoogle Scholar
• Johnson TM, Headington JT, Baker SR, Lowe L. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the ‘square’ procedure. J. Am. Acad. Dermatol.37(5 Pt 1), 758–764 (1997).
   PubMed Web of Science ®Google Scholar
• Moller MG, Pappas-Politis E, Zager JS et al. Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann. Surg. Oncol.16(6), 1526–1536 (2009).
   PubMed Web of Science ®Google Scholar
• Jejurikar SS, Borschel GH, Johnson TM, Lowe L, Brown DL. Immediate, optimal reconstruction of facial lentigo maligna and melanoma following total peripheral margin control. Plast. Reconstr. Surg.120(5), 1249–1255 (2007).
   PubMed Web of Science ®Google Scholar
• Anderson KW, Baker SR, Lowe L, Su L, Johnson TM. Treatment of head and neck melanoma, lentigo maligna subtype: a practical surgical technique. Arch. Facial Plast. Surg.3(3), 202–206 (2001).
   PubMedGoogle Scholar
• Sladden MJ, Balch C, Barzilai DA et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst. Rev.4, CD004835 (2009).
   Google Scholar
• Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br. J. Dermatol.143(4), 843–845 (2000).
   PubMed Web of Science ®Google Scholar
• Chapman MS, Spencer SK, Brennick JB. Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch. Dermatol.139(7), 943–944 (2003).
   PubMedGoogle Scholar
• Naylor MF, Crowson N, Kuwahara R et al. Treatment of lentigo maligna with topical imiquimod. Br. J. Dermatol.149(Suppl. 66), 66–70 (2003).
   PubMed Web of Science ®Google Scholar
• Powell AM, Russell-Jones R. Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy. J. Am. Acad. Dermatol.50(5), 792–796 (2004).
   PubMed Web of Science ®Google Scholar
• Fleming CJ, Bryden AM, Evans A, Dawe RS, Ibbotson SH. A pilot study ofMunoz CM, Sanchez JL, Martin-Garcia RF. Successful treatment of persistent melanoma in situ with 5% imiquimod cream. Dermatol. Surg.30(12 Pt 2), 1543–1545 (2004).
   PubMedGoogle Scholar
• Munoz CM, Sanchez JL, Martin-Garcia RF. Successful treatment of persistent melanoma in situ with 5% imiquimod cream. Dermatol. Surg.30(12 Pt 2), 1543–1545 (2004).
   PubMedGoogle Scholar
• Kupfer-Bessaguet I, Guillet G, Misery L, Carre JL, Leroy JP, Sassolas B. Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation. J. Am. Acad. Dermatol.51(4), 635–639 (2004).
   PubMedGoogle Scholar
• Wolf IH, Cerroni L, Kodama K, Kerl H. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch. Dermatol.141(4), 510–514 (2005).
   PubMedGoogle Scholar
• Spenny ML, Walford J, Werchniak AE et al. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. Cutis.79(2), 149–152 (2007).
   PubMed Web of Science ®Google Scholar
• Hopson B, Richey D, Sajben FP. Treatment of lentigo maligna with imiquimod 5% cream. J. Drugs Dermatol.6(10), 1037–1040 (2007).
   PubMedGoogle Scholar
• Mahoney MH, Joseph MG, Temple C. Topical imiquimod therapy for lentigo maligna. Ann. Plast. Surg.61(4), 419–424 (2008).
   PubMed Web of Science ®Google Scholar
• Ventura F, Rocha J, Fernandes JC, Pardal F, Brito C. Topical Imiquimod Treatment of Lentigo Maligna. Case Rep. Dermatol.1(1), 78–81 (2009).
   PubMedGoogle Scholar
• Powell AM, Robson AM, Russell-Jones R, Barlow RJ. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br. J. Dermatol.160(5), 994–998 (2009).
   PubMed Web of Science ®Google Scholar
• Demirci H, Shields CL, Bianciotto CG, Shields JA. Topical imiquimod for periocular lentigo maligna. Ophthalmology117(12), 2424–2429 (2010).
   PubMedGoogle Scholar
• O’Neill J, Ayers D, Kenealy J. Periocular lentigo maligna treated with imiquimod. J. Dermatol. Treat.22(2), 109–112 (2010).
   PubMedGoogle Scholar
• Cotter MA, McKenna JK, Bowen GM. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol. Surg.34(2), 147–151 (2008).
   PubMedGoogle Scholar
• van Meurs T, van Doorn R, Kirtschig G. Recurrence of lentigo maligna after initial complete response to treatment with 5% imiquimod cream. Dermatol. Surg.33(5), 623–626 (2007).
   PubMed Web of Science ®Google Scholar
• Fisher GH, Lang PG. Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Arch. Dermatol.139(7), 945–947 (2003).
   PubMedGoogle Scholar
• van Meurs T, Van Doorn R, Kirtschig G. Treatment of lentigo maligna with imiquimod cream: a long-term follow-up study of 10 patients. Dermatol. Surg.36(6), 853–858 (2010).
   PubMedGoogle Scholar
• Woodmansee CS, McCall MW. Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod. Dermatol. Surg.35(8), 1286–1289 (2009).
   PubMed Web of Science ®Google Scholar
• Tannous ZS, Mihm MC, Flotte TJ, Gonzalez S. In vivo examination of lentigo maligna and malignant melanoma in situ, lentigo maligna type by near-infrared reflectance confocal microscopy: comparison of in vivo confocal images with histologic sections. J. Am. Acad. Dermatol.46(2), 260–263 (2002).
   PubMed Web of Science ®Google Scholar
• Curiel-Lewandrowski C, Williams CM, Swindells KJ et al. Use of in vivo confocal microscopy in malignant melanoma: an aid in diagnosis and assessment of surgical and nonsurgical therapeutic approaches. Arch. Dermatol.140(9), 1127–1132 (2004).
   PubMedGoogle Scholar
• Chen CS, Elias M, Busam K, Rajadhyaksha M, Marghoob AA. Multimodal in vivo optical imaging, including confocal microscopy, facilitates presurgical margin mapping for clinically complex lentigo maligna melanoma. Br. J. Dermatol.153(5), 1031–1036 (2005).
   PubMed Web of Science ®Google Scholar